Collaborations & Alliances

Philochem Licenses OncoACP3 Worldwide Rights to RayzeBio

OncoACP3 is a small molecule ligand with high affinity and specificity for Acid Phosphatase 3 (ACP3), a novel target in prostate cancer.

Author Image

By: Charlie Sternberg

Associate Editor

Philochem AG, a wholly-owned subsidiary of the Philogen Group, and RayzeBio Inc., a wholly-owned subsidiary of Bristol-Myers Squibb, have inked a definitive agreement under which Philochem will license the exclusive worldwide rights to develop, manufacture, and commercialize OncoACP3, a clinical stage therapeutic and diagnostic agent targeting prostate cancer, to RayzeBio. OncoACP3, a small molecule ligand with exceptional affinity and specificity for Acid Phosphatase 3 (ACP3), a novel target...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters